Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.37 |
| ▸ | JUN | P05412 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92583 | 0.89 | SMN1; SMN2 (0.39) | KMT2ASMN1; SMN2SCDFAAHRAB9A | |
| SCHEMBL92443 | 0.87 | SCD (0.52) | SMN1; SMN2SCDCCR2 | |
| SCHEMBL91602 | 0.82 | KMT2A (0.43) | KMT2ASMN1; SMN2EPHX2SCDFAAH | |
| SCHEMBL91497 | 0.78 | SCD (0.51) | SMN1; SMN2SCD | |
| SCHEMBL29382268 | 0.77 | SMN1; SMN2 (0.56) | KMT2ASMN1; SMN2EPHX2SCDRAB9A | |
| SCHEMBL68900 | 0.77 | SMN1; SMN2 (0.56) | KMT2ASMN1; SMN2EPHX2SCDRAB9A | |
| SCHEMBL69860 | 0.75 | HIF1A (0.52) | KMT2ASMN1; SMN2FAAHRAB9ALMNA | |
| SCHEMBL29385107 | 0.75 | HIF1A (0.52) | KMT2ASMN1; SMN2FAAHRAB9ALMNA | |
| SCHEMBL68919 | 0.75 | SMN1; SMN2 (0.54) | KMT2ASMN1; SMN2EPHX2SCDRAB9A | |
| SCHEMBL92437 | 0.75 | CCR2 (0.40) | KMT2ASMN1; SMN2FAAHRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | KMT2A 1352/4885SMN1; SMN2 3937/4885EPHX2 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.